<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531218</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number: 2011-000808-18</org_study_id>
    <nct_id>NCT01531218</nct_id>
  </id_info>
  <brief_title>Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea</brief_title>
  <acronym>Concisus2012</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Trial Of Azithromycin In Campylobacter Concisus Positive Patients With Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slagelse Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial of azithromycin in
      Campylobacter concisus culture positive patients with diarrhea. The clinical characteristics
      of emerging Campylobacter concisus in adults is vomiting and persistent diarrhea. Whether
      patients may benefit from antibiotic treatment is unknown. The purpose of this trial is to
      investigate whether antibiotic treatment with azithromycin of Campylobacter concisus induced
      diarrhea can better the symptoms and shorten the duration of illness.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of diarrhea in days</measure>
    <time_frame>up to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of stools/day</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diarrhea</condition>
  <condition>Fever</condition>
  <condition>Vomiting</condition>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azithromycin 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 500mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg</description>
    <arm_group_label>azithromycin</arm_group_label>
    <other_name>zitromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with culture-positive stool sample with Campylobacter concisus

          -  Diarrheic patients â‰¥ 18 years

          -  symptoms of diarrhea defined as three or more watery stools per day or

          -  two watery stools per day + at least one of the following symptoms: abdominal pain,
             nausea, vomiting or fever.

          -  Diarrheic symptoms for a minimum of 24 hours before enrollment.

          -  Diarrheic symptoms for a maximum of 21 days before enrollment.

          -  Informed oral and signed written consent, with documentation that all relevant
             information about the study is given to the patient.

          -  The patient must be willing and able to participate in the trial.

        Exclusion Criteria:

          -  Hypersensitivity to azithromycin, erythromycin, macrolide or other
             ketolide-antibiotics

          -  Pregnancy or breastfeeding (if relevant).

          -  Culture positive stool sample with a Co-pathogen.

          -  Treatment with other antibiotics (in any stage 21 days before the first stool sample).

          -  Patients with severe liver disease.

          -  Patients with severe renal impairment (GFR &lt;10 ml / min).

          -  Patients with congenital or documented acquired QT prolongation.

          -  Patients treated with other active drugs that prolong the QT interval such as:
             antiarrhythmics of classes IA and III, cisapride and terfenadine.

          -  Patients with electrolyte disorders, particularly hypokalemia and hypomagnesemia.

          -  Patients with clinically relevant bradycardia, arrhythmia or severe heart failure.

          -  Inflammatory bowel diseases

          -  Chronic diarrhea of known cause.

          -  Dementia.

          -  Serious illness less than 21 days from the planned entry into the study.

          -  Patients treated with medications that have interactions with azithromycin e.g.
             alkaloids, ciclosporin or amiodarone.

          -  Patients involved in the planning or execution of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Campylobacter</keyword>
  <keyword>concisus</keyword>
  <keyword>diarrhea</keyword>
  <keyword>fever</keyword>
  <keyword>abdominal pain</keyword>
  <keyword>vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

